HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antigenic cross-reactivity between adenocarcinoma of the breast and fibrocystic disease of the breast.

Abstract
Peripheral lymphocytes obtained from 12 of 13 patients who had fibrocystic disease (FCD) of the breast were specifically cytotoxic to breast adenocarcinoma cells, as measured in vitro by the microcytotoxicity test. Sera from 6 women with active FCD or metastatic breast cancer could specifically block the cytotoxicity of lymphocytes from either population of patients against cancer cells. This implied extensive antigenic cross-reactivity between benign and malignant hyperplastic disease of the breast. Sera from 4 individuals clinically free of FCD or breast fibroadenoma (FAD) neutralized the blocking activity in the sera of patients with metastatic breast cancer. Patients "cured" of FCD or FAD represented a pool of potential plasma donors for immunotherapy of recurrent breast cancer.
AuthorsF Avis, I Avis, J F Newsome, G Haughton
JournalJournal of the National Cancer Institute (J Natl Cancer Inst) Vol. 56 Issue 1 Pg. 17-25 (Jan 1976) ISSN: 0027-8874 [Print] United States
PMID1255745 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antigens, Neoplasm
Topics
  • Adenofibroma (blood)
  • Antigens, Neoplasm
  • Breast Neoplasms (immunology)
  • Cross Reactions
  • Cysts (blood, immunology)
  • Cytotoxicity Tests, Immunologic
  • Female
  • Humans
  • Lymphocytes (immunology)
  • Neoplasm Metastasis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: